A phase II study of high dose ifosfamide in metastatic colorectal cancer

Pre‐Treatment of human osteosarcoma cells with N‐methylformamide enhances P‐glycoprotein expression and resistance to doxorubicin

“…NMF exerts a wide spectrum of biological and antineoplastic effects, including enhanced differentiation in leukemic and colorectal tumor cell lines, decreased proliferation not associated with cytotoxicity in different neoplastic cells and in vivo anti-tumor activity against experimental primary and metastatic tumors (Iwakawa et al, 1987;Langdon et al, 1988;Clagett-Carr et al, 1988;Greco et al, 1990). Although NMF failed to demonstrate significant effects in patients with carcinoma, leukemia or melanoma (McGuire et al, 1990;Murphy et al, 1987;Planting et al, 1987;Eton et al, 1991), recent studies have renewed interest in using NMF in sequential combination with chemotherapeutic agents (Zupi et al, 1988;Iwakawa et al, 1989;Laudonio et al, 1990;Cucco et al, 1991). In particular, NMF improves the lethal effects of doxorubicin (DXR) and 5-fluorouracil (5-FU), this effect being strictly dependent on the timing of exposure to drug.…”